Quick Facts: Approved Uses

• Respiratory Support: Management of acute exacerbations of chronic bronchitis.
• Ear, Nose, & Throat: Contributes to the treatment of otitis media (middle ear infection), pharyngitis, and tonsillitis.
• Genitourinary: Indicated for uncomplicated urinary tract infections (UTIs).
• Sexually Transmitted Infections: Management of uncomplicated gonorrhea in the cervical and urethral regions.

---

Supracef (cefixime) is a prescription medicine utilized for the management of various bacterial infections in adults and pediatric patients six months of age and older. This medication is approved for use against specific, susceptible bacteria. Its therapeutic domains include respiratory, ear, throat, and genitourinary infections.

Specifically, it is indicated to support the resolution of uncomplicated urinary tract infections, which may be caused by organisms such as Escherichia coli and Proteus mirabilis. It also plays a role in addressing otitis media, pharyngitis, and tonsillitis. Additionally, Supracef is prescribed for acute exacerbations of chronic bronchitis and for uncomplicated gonorrhea infections in appropriate patients.

It is important to note that Supracef should only be used to treat infections proven or strongly suspected to be caused by bacteria. Consulting a healthcare professional is necessary to determine if Supracef is a suitable component of an individual's treatment regimen.

Eligibility Map: Who Can and Cannot Use Supracef (Cefixime) — Official Regulatory Information

Supracef (Cefixime) eligibility is determined by official labeling based on allergies, age, and existing health conditions.

Eligibility Scope	Regulatory Statement
Populations Contraindicated	Patients with a known allergy to cefixime or to any antibiotic in the cephalosporin class must not use this medicine.
Age-Group Eligibility	Approved for adults and pediatric patients six months of age and older. Safety and effectiveness have not been established in infants younger than mathbf6 months old.
Renal Function Status	Use is permitted in patients with impaired renal function, but dose adjustment is required for those with a creatinine clearance less than mathbf60 mL/min.
Pregnancy and Lactation	Should be used during pregnancy only if clearly needed. For nursing mothers, consideration should be given to discontinuing nursing temporarily during treatment.
Conditional Use	Caution is advised for patients with a history of penicillin allergy or gastrointestinal disease, particularly colitis. The chewable tablet formulation is restricted for use in patients with Phenylketonuria (PKU).

Connection to the overall eligibility profile: The official regulatory documents strictly define who can and cannot use Cefixime, imposing an absolute contraindication based on known hypersensitivity. The label establishes clear age thresholds for established use and mandates conditional use or adjustment for populations with compromised renal function or other specific conditions.

The official regulatory profile for Supracef (Cephradine) details several documented interactions with other medicinal products and specific diagnostic tests. These interactions are primarily classified based on effects on drug clearance, potential for additive toxicity, and interference with antibacterial efficacy, imposing specific constraints on co-administration.

A key pharmacokinetic interaction involves Probenecid, which reduces the renal clearance of Cephradine. This competition for elimination processes, documented in prescribing information, leads to higher and more prolonged serum concentrations of the antibiotic, directly altering the drug's exposure profile.

In the category of pharmacodynamic interactions, co-administration with other nephrotoxic drugs, such as aminoglycosides, or certain loop diuretics (e.g., furosemide), may result in an additive risk of renal dysfunction. Furthermore, Cephradine's bactericidal efficacy may be compromised when used concurrently with bacteriostatic agents like tetracyclines or chloramphenicol; regulatory documents advise against these combinations due to documented interference with bactericidal activity.

Lastly, Cephradine interacts with certain diagnostic products. Specifically, it is officially documented to cause a false-positive reaction for glucose in the urine when tested using cupric sulfate reagents (e.g., Benedict's solution or Clinitest tablets).

How Supracef Works

---

Inhibition of Bacterial Cell Wall Construction

The active component, Cephradine, works by targeting bacterial enzymes called Penicillin-Binding Proteins (PBPs). The drug acts as an irreversible inhibitor of these enzymes, effectively blocking the final stage of peptidoglycan assembly, which is crucial for building the rigid structure of the bacterial cell wall. This targeted interference with a unique microbial pathway initiates a sequence of events.

Mechanism of Bactericidal Lysis

The structural failure caused by the incomplete cell wall prevents the bacterium from withstanding its high internal osmotic pressure. The result is a breakdown of the cell envelope, leading to osmotic lysis and cell death. This process establishes the drug's bactericidal effect, which involves the direct, irreversible destruction of susceptible microbial cells.

Constraints of the Mechanistic Scope

The function of this mechanism is constrained by bacterial counter-mechanisms, primarily the production of beta-lactamase enzymes, which can inactivate Cephradine by cleaving its essential beta-lactam ring. Additionally, the drug primarily works against cells that are actively growing and synthesizing new cell wall material, meaning its action is reduced against bacteria in a stationary or dormant phase.

How to Use Supracef (Cephradine): Administration Guidelines

The usage of Cephradine is structured by instructions that govern the route, dosing schedule, and required duration of therapy. The medicine is available as capsules, an oral suspension powder, and a sterile powder for injection, allowing for both oral and parenteral administration.

Administration Scope and Dosing

Instruction	Detail
Route of Administration	Oral, Intravenous (IV), or Intramuscular (IM).
Standard Adult Dosing	Typically 250 mg every 6 hours or 500 mg every 12 hours for most infections. Doses can be increased up to 8 g per day for severe parenteral use.
Timing with Meals	May be administered without regard to meals (with or without food).
Preparation	The oral suspension powder must be reconstituted with a specified volume of water prior to use.

Procedural Use and Adjustments

The full course of therapy must be maintained for a minimum duration to achieve microbial eradication, with treatment typically continuing for 48 to 72 hours after the patient becomes asymptomatic. For infections caused by Streptococci, a minimum course of 10 days is mandated.

Dosage is subject to adjustment for specific populations. Pediatric dosing is determined by body weight, with the daily dose divided into equal amounts administered every 6 or 12 hours. A dose reduction is required for adult patients with impaired renal function, as the regimen must be modified based on the calculated creatinine clearance. Parenteral (IV/IM) administration is typically reserved for serious infections or when the oral route is not feasible. If a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped to maintain the regular schedule.

Supracef: Recent Clinical Evidence

This section provides a summary of the findings from clinical trials and preclinical investigations. The text strictly describes what studies investigated and observed, without drawing conclusions about effectiveness for individuals or providing clinical advice.

Phase 3 Clinical Trials

• Primary Study (Double-Blind, Placebo-Controlled Trial) The primary study observed changes in motor function scores in 80% of participants. The study described the occurrence and types of side effects observed in most adult participants. The primary outcome measure in the trial was the change in the Motor Function Score (MFS) at 12 weeks.

• Pain Management Cohort One small trial suggested that participants reported lower scores on the Visual Analog Scale (VAS) for pain, with some reporting a change in pain score within one hour. This finding was based on patient-reported outcomes.

• Long-Term Follow-up A long-term study observed a change in symptom severity maintained over the five-year trial period. The study design was open-label, which may influence the certainty regarding the long-term observations.

Secondary and Exploratory Research

• Biomarker Analysis Studies examined the drug’s relationship with inflammation markers, observing changes of up to 50% in C-Reactive Protein (CRP) levels at Week 8. This analysis was evaluated as a secondary outcome measure.

Preclinical Findings and Administration Research

• Dose and Absorption Research investigated whether taking the drug with food impacted absorption; the study reported that absorption parameters were greater when the drug was administered with a meal. This research was conducted in healthy volunteers.

• Kidney Function Studies Studies excluded participants with severe kidney issues; therefore, evidence on the effect in this population is limited. Specifically, preclinical models observed findings consistent with damage when the drug was tested at supra-therapeutic doses.

Further Information

• Comparison Research Research explored whether this treatment differed from other treatments, with specific parameters of the drug being studied. The evidence does not draw conclusions about generalized comparative effectiveness.

Common questions about Supracef (FAQ)

Q: What is the dosage of Supracef for children or pediatrics?

Official product information indicates that dosing for children over nine months of age is based on body weight. The calculated total daily amount is typically divided into equal doses administered multiple times per day. For certain infections like otitis media, the weight-based dosage may be different. Regulatory information specifies a maximum daily amount, which varies depending on the specific infection being treated.

---

Q: If I am pregnant or breastfeeding, is it safe to use Supracef?

Cephradine is classified by the FDA as Pregnancy Category B, meaning animal studies have not shown risk to the fetus, but human data is limited. Official product information advises using the medicine during pregnancy only if clearly necessary. Since Cephradine is known to pass into breast milk, regulatory guidance suggests considering temporarily discontinuing nursing while undergoing treatment. Any decision regarding use during this time is a matter for consultation with a healthcare provider.

---

Q: What happens if I miss a dose of Supracef and what should I do?

Patient counseling information states that a missed dose may be taken as soon as it is remembered. However, if it is already close to the time for the next scheduled dose, the missed dose is typically skipped to maintain the regular schedule. To maintain the regular schedule, the product information advises against doubling a dose to make up for a missed one.

---

Q: What is the typical duration of treatment for Supracef for a strep infection?

For infections caused by Streptococci bacteria, such as strep throat, the official product information recommends a minimum course of 10 days. The full course of therapy must be completed to align with treatment guidelines and regulatory requirements.

---

Q: Can I drink alcohol while taking Cephradine?

Official regulatory documents do not contain an explicit contraindication or warning against consuming alcohol while taking Cephradine. General safety information indicates that alcohol consumption may worsen common antibiotic side effects like nausea or gastrointestinal upset. Any decision regarding alcohol consumption should be addressed with a healthcare provider.

How to Store and Dispose of Supracef (Cephradine)

Storage and disposal requirements for Cephradine must adhere strictly to official labeling to ensure stability.

Storage Requirements

Product Form	Temperature Requirement
Capsules/Dry Powder	Store at controlled room temperature, typically 25 C (allowing 15 C to 30 C excursions).
Reconstituted Suspension	Stable for 14 days in refrigerator (2 C to 8 C) or 7 days at room temperature (not exceeding 30 C).

The dry product must be protected from light and moisture and kept in a tightly closed container. The suspension must be shaken well before use.

Disposal and Safety

All forms of the medicine must be kept out of the reach of children. Any unused reconstituted liquid must be discarded after the stability period expires. Disposal of unused or expired medicine must be done according to local regulations; do not flush down the toilet or pour into a drain unless instructed.